BioSpace News Archive

RTI Surgical Holdings, Inc. announced that it has set a new record date for the special meeting of its shareholders

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2019. “2019 was a critical year for Adu

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update. “Crinetics made significant progress in 2019 advancing our development programs, as highlighted by

American Renal Associates Holdings, Inc., a leading kidney care and dialysis provider focused on partnering with local nephrologists, announced that it will hold its fourth quarter 2019 earnings conference call on Monday, March 16, 2020 at 5:00 p.m..

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced that the underwriters of its previously announced initial public offering of 12,000,000 shares of common stock have exercised their option to purchase additional shares of common stock at the public offering price of $18.00

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company’s Chief Financial Officer, will hold a virtual presentation at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 at 1:35 PM ET. The live and archived webcast of the presentation will be accessible from the

Letter of Intent Provides for Continued Local Governance, Ongoing Community Commitment

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it plans to initiate development of MN-166 for severe pneumonia and acute respiratory distress syndrome.

Blue Cross and Blue Shield of Kansas City announces it is taking specific steps to ensure our members’ access to testing, medications and virtual care, as it monitors the spread of the new coronavirus, or COVID-19.

As coronavirus paralyzes the world with fear, bioscience enterprise The Gilla Company has developed and independently tested a product shown to be at least 99.9% effective in killing the deadly virus.